LLY is trading at $1061.76 (+4.01%) in pre-market, rebounding sharply from yesterday's drop following the release of its Q4 2025 financial results.
- Revenue surged 43% to $19.3B driven by massive demand for Mounjaro and Zepbound, while non-GAAP EPS rose 42% to $7.54.
- The recovery is fueled by upbeat 2026 guidance, which has restored investor confidence after the stock fell -7.79% in the previous session.